ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
February 29, 2024 07:57 ET | ZyVersa Therapeutics
ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
February 28, 2024 07:57 ET | ZyVersa Therapeutics
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024 01:00 ET | Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
Fractyl-Logo.png
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
February 20, 2024 08:38 ET | Fractyl Health, Inc.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
NodThera_logo.jpg
NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors
February 19, 2024 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors ...
NodThera_logo.jpg
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
February 05, 2024 07:00 ET | NodThera
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
Fractyl-Logo.png
Fractyl Health Announces Pricing of Initial Public Offering
February 01, 2024 20:08 ET | Fractyl Health, Inc.
Fractyl Health (Nasdaq: GUTS), announces pricing of initial public offering.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
January 31, 2024 07:57 ET | ZyVersa Therapeutics
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
NEWEST DSS_logo1.png
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."
January 30, 2024 08:05 ET | DSS, Inc.
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative...
GLP-1 receptor agonist-based compounds are the most common drug class in late stage clinical trials
Airfinity launches world’s first obesity data and analytics platform
January 24, 2024 04:57 ET | Airfinity
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market.  ...